HansBiomed Corporation
HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralize… Read more
HansBiomed Corporation (042520) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.036x
Based on the latest financial reports, HansBiomed Corporation (042520) has a cash flow conversion efficiency ratio of 0.036x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.21 Billion) by net assets (₩33.89 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
HansBiomed Corporation - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how HansBiomed Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
HansBiomed Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HansBiomed Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MOIL Limited
NSE:MOIL
|
0.050x |
|
Grab Holdings Limited Warrant
NASDAQ:GRABW
|
-0.019x |
|
Hwaway Tech Corp Ltd
SHE:001380
|
N/A |
|
PRIMIS FINANCIAL DL-01
F:7H80
|
N/A |
|
TomTom N.V
PINK:TMOAF
|
0.061x |
|
Golden Friends
TWO:4506
|
0.089x |
|
Skytech Inc.
TW:6937
|
-0.047x |
|
FD Technologies Plc
PINK:FDRVF
|
0.070x |
Annual Cash Flow Conversion Efficiency for HansBiomed Corporation (2012–2025)
The table below shows the annual cash flow conversion efficiency of HansBiomed Corporation from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | ₩33.89 Billion | ₩318.34 Million | 0.009x | -64.14% |
| 2024-09-30 | ₩67.12 Billion | ₩1.76 Billion | 0.026x | +135.06% |
| 2023-09-30 | ₩49.95 Billion | ₩-3.73 Billion | -0.075x | +20.13% |
| 2022-09-30 | ₩45.63 Billion | ₩-4.27 Billion | -0.094x | +71.60% |
| 2021-09-30 | ₩44.45 Billion | ₩-14.64 Billion | -0.329x | -445.66% |
| 2020-09-30 | ₩60.34 Billion | ₩5.75 Billion | 0.095x | +3.88% |
| 2019-09-30 | ₩84.07 Billion | ₩7.71 Billion | 0.092x | +15.14% |
| 2018-09-30 | ₩65.30 Billion | ₩5.20 Billion | 0.080x | -23.50% |
| 2017-09-30 | ₩53.73 Billion | ₩5.60 Billion | 0.104x | +1642.90% |
| 2016-09-30 | ₩46.82 Billion | ₩-316.10 Million | -0.007x | -108.41% |
| 2015-09-30 | ₩43.16 Billion | ₩3.47 Billion | 0.080x | +53.45% |
| 2014-09-30 | ₩39.39 Billion | ₩2.06 Billion | 0.052x | -34.24% |
| 2013-09-30 | ₩29.31 Billion | ₩2.33 Billion | 0.080x | +27.45% |
| 2012-09-30 | ₩24.04 Billion | ₩1.50 Billion | 0.062x | -- |